Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Droescher is active.

Publication


Featured researches published by Peter Droescher.


Steroids | 1997

Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidative activities: 17α-substituted analogs of Δ9(11)-dehydro-17β-estradiol

Wolfgang Römer; Michael Oettel; Bernd Menzenbach; Peter Droescher; Sigfrid Schwarz

Abstract Antioxidant effects of N,N-dimethyl-p-toluidine, p-cresol, and p-(hydroxy)thioanisol 17α-substituted analogs of 17β-estradiol and their Δ9(11)-dehydro homologs were investigated using four different in vitro models: rat synaptosomal lipid peroxidation induced by Fentons reagent, Fe(II)-chelating activities, the formation of superoxide anion radicals, and total antioxidative activity. Whereas the classical estrogen 17β-estradiol as well as selected phenolic compounds was only moderately inhibiting iron-dependent lipid peroxidation and stimulating total antioxidative activity, besides Δ9(11)-dehydro-17β-estradiol (J 1213), novel estrogens such as C-17-oriented side chain analogs of 17β-estradiol (J 843, J 872, and J 897) and Δ9(11)-dehydro homologs (J 844, J 864, and J 898) directly altered the iron redox chemistry and diminished the formation of superoxide anion radicals generated by a xanthine/xanthine oxidase-dependent luminescence reaction to a great extent. These results suggest that definite modifications in the chemical structure of 17β-estradiol, e.g., the introduction of a Δ9(11)-double bond and/or p-cresol as well as p-(hydroxy)thioanisol C-17 substitution, may result in substantial changes in their antioxidant behavior. These compounds may be drug candidates for treating pathologies related to free radical formation.


Bioorganic & Medicinal Chemistry Letters | 2009

Structure-based design, synthesis and in vitro characterization of potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone

Gabriele Möller; Dominga Deluca; Christian Gege; Andrea Rosinus; Dorota Kowalik; Olaf Peters; Peter Droescher; Walter Elger; Jerzy Adamski; Alexander Hillisch

In search for specific drugs against steroid-dependent cancers we have developed a novel set of potent inhibitors of steroidogenic human 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD 1). The X-ray structure of 17beta-HSD 1 in complex with estradiol served as basis for the design of the inhibitors. 2-Substituted estrone and D-homo-estrone derivatives were synthesized and tested for 17beta-HSD 1 inhibition. The best 17beta-HSD 1 inhibitor, 2-phenethyl-D-homo-estrone, revealed an IC(50) of 15 nM in vitro. The inhibitory potency of compounds is comparable or better to that of previously described inhibitors. An interaction within the cofactor binding site is not necessary to obtain this high binding affinity for substances developed.


Steroids | 2003

The significance of the 20-carbonyl group of progesterone in steroid receptor binding: a molecular dynamics and structure-based ligand design study

Alexander Hillisch; Johannes von Langen; Bernd Menzenbach; Peter Droescher; Günter Kaufmann; Birgitt Schneider; Walter Elger

Polar functional groups in the A- and D-ring (positions 3 and 17beta or 20) are common to all natural and synthetic steroid hormones. It was assumed that these pharmacophoric groups are involved in strong hydrogen bonding interactions with the respective steroid receptors. High resolution X-ray structures of the estrogen and androgen receptors have confirmed these assumptions. Also site-directed mutagenesis studies of the human progesterone receptor (hPR) suggest an important role for Cys891 in the recognition of the progesterone 20-carbonyl group. Surprisingly, the crystal structure of the hPR ligand binding domain (LBD) in complex with progesterone suggests that the carbonyl oxygen in position 20 (O20) is not involved in hydrogen bond contacts. To investigate these surprising and contradicting results further, we performed a molecular dynamics simulation of the hPR-progesterone complex in an aqueous environment. The simulation revealed hPR-Cys891 as the sole but weak hydrogen bonding partner of progesterone in the D-ring. In contrast to the site-directed mutagenesis data a major role of hPR-Cys891 in progesterone recognition could not be confirmed. Isolated hydrogen bond acceptors, such as the prosterone O20 group, in a relatively lipophilic environment of the receptor led to a decrease in affinity of the ligand. Based on this consideration and the structure of the PR, we designed compounds lacking such an acceptor function. If the X-ray structure and the calculations were right, these compounds should bind with comparable or higher affinity versus that of progesterone. E-17-Halomethylene steroids were synthesized and pharmacologically characterized in vitro and in vivo. Although the compounds are unable to form hydrogen bonds with the hPR in the D-ring region, they bind with superior affinity and exert stronger in vivo progestational effects than progesterone itself. Our investigations have confirmed the results of the X-ray structure and disproved the old pharmacophore model for progestogenic activity, comprising two essential polar functional groups on both ends of the steroid core. The 20-carbonyl group of progesterone is likely to play a role beyond PR-binding, e.g. in the context of other functions via the androgen and mineralocorticoid receptors and as a site of metabolic inactivation.


Archive | 2001

Non-steroidal inflammation inhibitors

Stefan Jaroch; Manfred Lehmann; Norbert Schmees; Bernd Buchmann; Hartmut Rehwinkel; Peter Droescher; Werner Skuballa; Konrad Krolikiewicz; Hartwig Hennekes; Heike Schäcke; Arndt Schottelius


Arthritis & Rheumatism | 2004

Nonsteroidal antiinflammatory agents

Stefan Jaroch; Manfred Lehmann; Norbert Schmees; Bernd Buchmann; Harmur Rehwinkel; Peter Droescher; Werner Skuballa; Konrad Krolikiewicz; Hartwig Hennekes; Heike Schaecke; Arndr Schottelius


Archive | 1998

Non-estrogenic estradiol derivative compounds with anti-oxidative activity

Peter Droescher; Bernd Menzenbach; Wolfgang Roemer; Birgitt Schneider; Walter Elger; Guenter Kaufmann


Archive | 2000

New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism

Stefan Jaroch; Manfred Lehmann; Norbert Schmees; Bernd Buchmann; Hartmut Rehwinkel; Peter Droescher; Werner Skuballa; Konrad Krolikiewicz; Hartwig Hennekes; Heike Schaecke; Arndt Schottelius


Archive | 2000

Ent-steroids as selectively active estrogens

Siegfried Schwarz; Dirk Kosemund; Gerd Müller; Margit Richter; Olaf Peters; Peter Droescher; Walter Elger; Alexander Hillisch; Ulf Bömer; Karl-Heinrich Fritzemeier; Christa Hegele-Hartung


Archive | 1994

Use of steroids with a phenolic a-ring structure for prophylaxis and therapy of radical-mediated cell damage

Peter Droescher; Bernd Menzenbach; Kurt Ponsold; Bernd Undeutsch; Michael Oettel; Wolfgang Römer; Günter Kaufmann; Jens Schroder


Archive | 1994

Steroids with radical-attracting aromatic substituents, process for the production thereof and pharmaceutical compounds containing the said substances

Peter Droescher; Bernd Menzenbach; Kurt Ponsold; Bernd Undeutsch; Michael Oettel; Wolfgang Römer; Günter Kaufmann; Jens Schroder

Collaboration


Dive into the Peter Droescher's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge